FDA Hits Avidity's AOC for Myotonic Dystrophy Type 1 with Partial Hold

FDA Hits Avidity's AOC for Myotonic Dystrophy Type 1 with Partial Hold

Submitted by admin on September 28, 2022 - 10:38am
Source: 
BioSpace
News Tags: 
Avidity Biosciences
AOC 1001
myotonic muscular dystrophy
FDA
clinical trials
Headline: 
FDA Hits Avidity's AOC for Myotonic Dystrophy Type 1 with Partial Hold
snippet: 

The FDA ordered Avidity Biosciences to halt clinical trial enrollment in a Phase I/II trial of AOC 1001 in myotonic dystrophy type 1 after a patient suffered a "serious adverse event", the company reported Tuesday. 

Do Not Allow Advertisers to Use My Personal information